Design Therapeutics, Inc. (DSGN)
15.11
-0.14
(-0.92%)
USD |
NASDAQ |
Aug 28, 16:00
15.09
-0.02
(-0.13%)
After-Hours: 20:00
Design Therapeutics Enterprise Value : 740.85M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 740.85M |
| August 27, 2026 | 749.61M |
| August 26, 2026 | 770.89M |
| August 25, 2026 | 776.52M |
| August 24, 2026 | 748.36M |
| August 21, 2026 | 733.34M |
| August 20, 2026 | 769.01M |
| August 19, 2026 | 792.79M |
| August 18, 2026 | 750.86M |
| August 17, 2026 | 740.23M |
| August 14, 2026 | 723.33M |
| August 13, 2026 | 695.79M |
| August 12, 2026 | 712.69M |
| August 11, 2026 | 710.19M |
| August 10, 2026 | 692.04M |
| August 07, 2026 | 670.76M |
| August 06, 2026 | 656.99M |
| August 05, 2026 | 644.48M |
| August 04, 2026 | 621.32M |
| August 03, 2026 | 593.79M |
| July 31, 2026 | 557.49M |
| July 30, 2026 | 585.03M |
| July 29, 2026 | 547.48M |
| July 28, 2026 | 538.09M |
| July 27, 2026 | 538.72M |
| Date | Value |
|---|---|
| July 24, 2026 | 532.46M |
| July 23, 2026 | 523.07M |
| July 22, 2026 | 532.46M |
| July 21, 2026 | 549.98M |
| July 20, 2026 | 538.09M |
| July 17, 2026 | 581.90M |
| July 16, 2026 | 584.40M |
| July 15, 2026 | 641.35M |
| July 14, 2026 | 650.74M |
| July 13, 2026 | 662.31M |
| July 10, 2026 | 745.86M |
| July 09, 2026 | 760.25M |
| July 08, 2026 | 751.49M |
| July 07, 2026 | 715.82M |
| July 06, 2026 | 724.58M |
| July 02, 2026 | 774.02M |
| July 01, 2026 | 712.69M |
| June 30, 2026 | 700.80M |
| June 29, 2026 | 669.08M |
| June 26, 2026 | 613.50M |
| June 25, 2026 | 619.12M |
| June 24, 2026 | 640.35M |
| June 23, 2026 | 637.86M |
| June 22, 2026 | 635.36M |
| June 18, 2026 | 556.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 277.08B |
| AnaptysBio, Inc. | 1.625B |
| 4D Molecular Therapeutics, Inc. | 487.87M |
| Inhibrx Biosciences, Inc. | 1.864B |
| Agenus, Inc. | 591.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.16M |
| Total Expenses (Quarterly) | 20.16M |
| EPS Diluted (Quarterly) | -0.3226 |
| Earnings Yield | -7.81% |
| Normalized Earnings Yield | -7.813 |